Sunday is usually a good day at ESMO congresses and 2017 was no different in that respect.

It does feel weird, however, to be seeing tweets about data from some studies hours before they are presented in that day’s Presidential Symposium, something oncologists attending have started to notice too:

Yesterday we had encouraging readouts from PACIFIC and FLAURA trials to discuss, so what’s in store for today? Are they mostly highights or lowlights?

Subscribers can log-in to read our latest insights from ESMO17 or you can gain access to BSB Premium Content.

Posted by